Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Hexaminolevulinate Hydrochloride in Non-Muscle Invasive Bladder Neoplasms: NCT06525571 Clinical Landscape Report 2026
16 October 2026
NCT06525571 clinical landscape for Non-Muscle Invasive Bladder Neoplasms: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
Sacituzumab govitecan-hziy in Urothelial Carcinoma of the Urinary Bladder: NCT06528483 Clinical Landscape Report 2026
16 October 2026
NCT06528483 clinical landscape for Urothelial Carcinoma of the Urinary Bladder: endpoints, sponsor, phase, geography, readouts, asset context and development…
9 min read
Cemiplimab-RWLC in Leiomyosarcoma: NCT06528769 Clinical Landscape Report 2026
16 October 2026
NCT06528769 clinical landscape for Leiomyosarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
ERX-315 in Liver metastases: NCT06533332 Clinical Landscape Report 2026
16 October 2026
NCT06533332 clinical landscape for Liver metastases: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
GC-012F in Systemic Lupus Erythematosus: NCT06530849 Clinical Landscape Report 2026
16 October 2026
NCT06530849 clinical landscape for Systemic Lupus Erythematosus: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Poly ICLC in Residual Neoplasm: NCT06529822 Clinical Landscape Report 2026
16 October 2026
NCT06529822 clinical landscape for Residual Neoplasm: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Paclitaxel in Liver metastases: NCT06532539 Clinical Landscape Report 2026
16 October 2026
NCT06532539 clinical landscape for Liver metastases: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
ALTA-2618 in Endometrial Carcinoma: NCT06533059 Clinical Landscape Report 2026
16 October 2026
NCT06533059 clinical landscape for Endometrial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Amulirafusp alfa in Systemic Lupus Erythematosus: NCT06535412 Clinical Landscape Report 2026
16 October 2026
NCT06535412 clinical landscape for Systemic Lupus Erythematosus: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
89Zr-TLX300-CDx in Soft Tissue Sarcoma: NCT06537596 Clinical Landscape Report 2026
16 October 2026
NCT06537596 clinical landscape for Soft Tissue Sarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
XS-02 in Locally Advanced Malignant Solid Neoplasm: NCT06531486 Clinical Landscape Report 2026
16 October 2026
NCT06531486 clinical landscape for Locally Advanced Malignant Solid Neoplasm: endpoints, sponsor, phase, geography, readouts, asset context and development w…
9 min read
Temozolomide in Relapsed Solid Neoplasm: NCT06541262 Clinical Landscape Report 2026
16 October 2026
NCT06541262 clinical landscape for Relapsed Solid Neoplasm: endpoints, sponsor, phase, geography, readouts, asset context and development white space.